AngioDynamics, Inc. (ANGO) Position Trimmed by Russell Investments Group Ltd.
Russell Investments Group Ltd. decreased its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 59.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 126,609 shares of the medical instruments supplier’s stock after selling 189,254 shares during the quarter. Russell Investments Group Ltd. owned about 0.34% of AngioDynamics worth $2,052,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. OppenheimerFunds Inc. boosted its stake in AngioDynamics by 21.8% during the 1st quarter. OppenheimerFunds Inc. now owns 16,130 shares of the medical instruments supplier’s stock valued at $280,000 after purchasing an additional 2,883 shares during the period. Bank of Montreal Can boosted its stake in AngioDynamics by 126.1% during the 2nd quarter. Bank of Montreal Can now owns 262,846 shares of the medical instruments supplier’s stock valued at $4,261,000 after purchasing an additional 146,583 shares during the period. Highbridge Capital Management LLC bought a new stake in AngioDynamics during the 1st quarter valued at approximately $419,000. Great West Life Assurance Co. Can boosted its stake in AngioDynamics by 6.6% during the 1st quarter. Great West Life Assurance Co. Can now owns 43,489 shares of the medical instruments supplier’s stock valued at $754,000 after purchasing an additional 2,702 shares during the period. Finally, Comerica Bank boosted its stake in AngioDynamics by 5.8% during the 1st quarter. Comerica Bank now owns 35,175 shares of the medical instruments supplier’s stock valued at $537,000 after purchasing an additional 1,932 shares during the period. Hedge funds and other institutional investors own 95.80% of the company’s stock.
In related news, CEO James C. Clemmer purchased 20,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was acquired at an average cost of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the purchase, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,355,722.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James C. Clemmer purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was bought at an average price of $15.79 per share, with a total value of $78,950.00. Following the completion of the purchase, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders bought 25,316 shares of company stock worth $396,806 in the last ninety days. 1.88% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/04/angiodynamics-inc-ango-position-trimmed-by-russell-investments-group-ltd.html.
Shares of AngioDynamics, Inc. (ANGO) traded up 3.64% during mid-day trading on Monday, hitting $17.65. The company’s stock had a trading volume of 928,857 shares. The company has a market cap of $645.64 million, a price-to-earnings ratio of 128.83 and a beta of 1.14. The company has a 50-day moving average of $16.48 and a 200 day moving average of $16.22. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.35.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the consensus estimate of $0.16 by $0.03. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The company had revenue of $86.90 million for the quarter, compared to the consensus estimate of $90.72 million. During the same quarter in the prior year, the business earned $0.19 earnings per share. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. On average, analysts expect that AngioDynamics, Inc. will post $0.67 EPS for the current year.
Several analysts recently weighed in on the company. Canaccord Genuity restated a “hold” rating and set a $16.50 target price on shares of AngioDynamics in a research note on Wednesday, May 31st. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research note on Friday, August 25th. Cantor Fitzgerald increased their target price on AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Zacks Investment Research downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. AngioDynamics currently has an average rating of “Hold” and an average price target of $18.50.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.